{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:40:48Z","timestamp":1777581648243,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicine in Drug Discovery"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.medidd.2020.100052","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T05:04:50Z","timestamp":1591333490000},"page":"100052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19"],"prefix":"10.1016","volume":"7","author":[{"given":"B.","family":"Solun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medidd.2020.100052_bb0005","doi-asserted-by":"crossref","unstructured":"Ruan Q., Yang K., Wang W., et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.Intensive Care Med. 2020; (published online March 3).","DOI":"10.1007\/s00134-020-05991-x"},{"key":"10.1016\/j.medidd.2020.100052_bb0010","series-title":"Characteristics of and important lessons from the Coronavirus disease, 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese center for disease control and prevention JAMA","author":"Wu","year":"2020"},{"issue":"10223","key":"10.1016\/j.medidd.2020.100052_bb0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet."},{"issue":"10223","key":"10.1016\/j.medidd.2020.100052_bb0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China Lancet"},{"key":"10.1016\/j.medidd.2020.100052_bb0025","doi-asserted-by":"crossref","unstructured":"Yang X., Yu Y., Xu J., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 Feb 24. pii: S2213\u20132600(20)30079\u20135.","DOI":"10.1016\/S2213-2600(20)30079-5"},{"key":"10.1016\/j.medidd.2020.100052_bb0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan","author":"Wu","year":"2020","journal-title":"China JAMA Intern Med"},{"key":"10.1016\/j.medidd.2020.100052_bb0035","doi-asserted-by":"crossref","unstructured":"Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) \u2014 United States, February 12\u2013March 16, 2020; Weekly \/ March 27, 2020, 69(12);343-346; Morbidity and Mortality Weekly Report (MMWR).","DOI":"10.15585\/mmwr.mm6912e2"},{"issue":"4","key":"10.1016\/j.medidd.2020.100052_bb0040","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/jamp.2009.0775","article-title":"Acute Lung Injury: Epidemiology, Pathogenesis, and Treatment","volume":"23","author":"Johnson","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"10.1016\/j.medidd.2020.100052_bb0045","first-page":"11","article-title":"The epithelium in acute lung injury\/acute respiratory distress syndrome","volume":"14","author":"Gropper","year":"2008","journal-title":"Curr Opin Crit Care"},{"issue":"6","key":"10.1016\/j.medidd.2020.100052_bb0050","first-page":"419","article-title":"Epithelial cell apoptosis and lung remodeling","volume":"4","author":"Kuwano","year":"2007","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.medidd.2020.100052_bb0055","unstructured":"Infantino M., Damiani A., Gobbi FL., et al. Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations, and Perspectives.IMAJ, V.22, April 2020, P.203\u2013210."},{"issue":"3","key":"10.1016\/j.medidd.2020.100052_bb0060","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1183\/09031936.02.00272002","article-title":"Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD","volume":"20","author":"Di Stefano","year":"2002","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.medidd.2020.100052_bb0065","first-page":"693","article-title":"The 74th Annual Meeting President Lecture. Pathogenesis and therapy of acute lung injury","volume":"74","author":"Kitamura","year":"1999","journal-title":"Kekkaku."},{"issue":"5","key":"10.1016\/j.medidd.2020.100052_bb0070","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1165\/rcmb.2008-0348TR","article-title":"Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury","volume":"40","author":"Zemans","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"10.1016\/j.medidd.2020.100052_bb0075","doi-asserted-by":"crossref","first-page":"L1037","DOI":"10.1152\/ajplung.2001.281.5.L1037","article-title":"Transcriptional mechanisms of acute lung injury","volume":"281","author":"Fan","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"7","key":"10.1016\/j.medidd.2020.100052_bb0080","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2362.2009.02145.x","article-title":"Innate immune receptors on neutrophils and their role in chronic lung disease","volume":"39","author":"Koller","year":"2009","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.medidd.2020.100052_bb0085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bbi.2009.07.009","article-title":"Cynical hostility and stimulated Th1 and Th2 cytokine production","volume":"24","author":"Janicki-Deverts","year":"2010","journal-title":"Brain Behav Immun"},{"issue":"6","key":"10.1016\/j.medidd.2020.100052_bb0090","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.4049\/jimmunol.180.6.4191","article-title":"Dual modulation of airway smooth muscle contraction by Th2 cytokines via matrix metalloproteinase-1 production","volume":"180","author":"Ohta","year":"2008","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.medidd.2020.100052_bb0095","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2174\/138945006777435263","article-title":"Cytokines as targets in chronic obstructive pulmonary disease","volume":"7","author":"Chung","year":"2006","journal-title":"Curr Drug Targets"},{"issue":"4","key":"10.1016\/j.medidd.2020.100052_bb0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1440-1843.2009.01517.x","article-title":"Airway inflammation and anti-protease defenses rapidly improve during treatment of an acute exacerbation of COPD","volume":"14","author":"Pant","year":"2009","journal-title":"Respirology."},{"key":"10.1016\/j.medidd.2020.100052_bb0105","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0083-6729(06)74019-5","article-title":"Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases","volume":"74","author":"Joshi","year":"2006","journal-title":"Vitam Horm"},{"issue":"4","key":"10.1016\/j.medidd.2020.100052_bb0110","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1067\/mai.2003.1333","article-title":"IL-13 receptors and signaling pathways: an evolving web","volume":"111","author":"Hershey","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.medidd.2020.100052_bb0115","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.4049\/jimmunol.0803951","article-title":"Mast cell-dependent contraction of human airway smooth muscle cell-containing collagen gels: influence of cytokines, matrix metalloproteases, and serine proteases","volume":"183","author":"Margulis","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.medidd.2020.100052_bb0120","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.immunol.21.120601.141142","article-title":"IL-13 effector functions","volume":"21","author":"Wynn","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.medidd.2020.100052_bb0125","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2008.01.031","article-title":"Immunologic and inflammatory mechanisms that drive asthma progression to remodeling","volume":"121","author":"Broide","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.medidd.2020.100052_bb0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pcl.2012.03.002","article-title":"Making Sense of the Cytokine Storm: a conceptual framework for understanding, diagnosing and treating hemophagocytic syndromes","volume":"59","author":"Scott","year":"2012","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.medidd.2020.100052_bb0135","doi-asserted-by":"crossref","unstructured":"Moore JB, June CH. Cytokine release syndrome in severe COVID-19: Science 17 Apr 2020; eabb8925. doi: https:\/\/doi.org\/10.1126\/science.abb8925;","DOI":"10.1126\/science.abb8925"},{"key":"10.1016\/j.medidd.2020.100052_bb0140","doi-asserted-by":"crossref","first-page":"102538","DOI":"10.1016\/j.autrev.2020.102538","article-title":"Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning","volume":"5","author":"Shoenfeld","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.medidd.2020.100052_bb0145","unstructured":"Qing Ye 1, Bili Wang 1, Jianhua Mao. Cytokine Storm in COVID-19 and Treatment. J Infect.. 2020 Apr 10; S0163\u20134453(20)30165\u20131. [Online ahead of print];"},{"key":"10.1016\/j.medidd.2020.100052_bb0150","doi-asserted-by":"crossref","unstructured":"Mehta P., McAuley DF., Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet, V. 395, ISSUE 10229, P1033\u20131034, March 28, 2020.","DOI":"10.1016\/S0140-6736(20)30628-0"},{"issue":"5","key":"10.1016\/j.medidd.2020.100052_bb0155","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic Human Coronavirus Infections: Causes and Consequences of Cytokine Storm and Immunopathology","volume":"39","author":"Channappanavar","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.medidd.2020.100052_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2017.02.005","article-title":"Biochemical and Biological Attributes of Matrix Metalloproteinases","volume":"147","author":"Cui","year":"2017","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"4","key":"10.1016\/j.medidd.2020.100052_bb0165","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/1389203023380549","article-title":"Matrix metalloproteinases in lung diseases","volume":"3","author":"Ohbayashi","year":"2002","journal-title":"Curr Protein Pept Sci"},{"issue":"4","key":"10.1016\/j.medidd.2020.100052_bb0170","first-page":"323","article-title":"Biology of metalloproteinases","volume":"48","author":"Am\u0103linei","year":"2007","journal-title":"Rom J Morphol Embryol"},{"issue":"1","key":"10.1016\/j.medidd.2020.100052_bb0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1152\/physrev.00022.2006","article-title":"Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted","volume":"87","author":"Greenlee","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.medidd.2020.100052_bb0180","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1465-9921-6-148","article-title":"Induction and regulation of matrix metalloproteinase-12 in human airway smooth muscle cells","volume":"6","author":"Xie","year":"2005","journal-title":"Respir Res"},{"issue":"12","key":"10.1016\/j.medidd.2020.100052_bb0185","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2174\/138161209787846685","article-title":"Multiple roles of the extracellular matrix in inflammation","volume":"15","author":"Korpos","year":"2009","journal-title":"Curr Pharm Des"},{"issue":"1\u20133","key":"10.1016\/j.medidd.2020.100052_bb0190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2005.12.082","article-title":"Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases","volume":"533","author":"Gueders","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"10.1016\/j.medidd.2020.100052_bb0195","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1590\/S0100-879X2005001000009","article-title":"Role of matrix metalloproteinases in the development of airway inflammation and remodeling","volume":"38","author":"Lagente","year":"2005","journal-title":"Braz J Med Biol Res"},{"issue":"Suppl. 1","key":"10.1016\/j.medidd.2020.100052_bb0200","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1590\/S0074-02762005000900028","article-title":"Macrophage elastase (MMP-12): a pro-inflammatory mediator?","volume":"100","author":"N\u00e9nan","year":"2005","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.medidd.2020.100052_bb0205","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/thx.2005.051979","article-title":"Matrix metalloproteinases in destructive pulmonary pathology","volume":"61","author":"Elkington","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.medidd.2020.100052_bb0210","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.2174\/092986709787846587","article-title":"Matrix metalloproteinases in respiratory diseases: from pathogenesis to potential clinical implications","volume":"16","author":"Oikonomidi","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.medidd.2020.100052_bb0215","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1097\/CCM.0b013e3181a5506c","article-title":"Salbutamol up-regulates matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome","volume":"37","author":"O\u2019Kane","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.medidd.2020.100052_bb0220","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1183\/09031936.00032111","article-title":"Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair","volume":"38","author":"Davey","year":"2011","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.medidd.2020.100052_bb0225","first-page":"22","article-title":"Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer","volume":"1776","author":"Pampalakis","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.medidd.2020.100052_bb0230","doi-asserted-by":"crossref","unstructured":"Bryant JW., Shariat-Madar Z. Human plasma kallikrein-kinin system: physiological and biochemical parameters. Cardiovascular & Hematological Agents in Medicinal Chemistry, 01 Jul 2009, 7(3):234\u2013250.","DOI":"10.2174\/187152509789105444"},{"issue":"3","key":"10.1016\/j.medidd.2020.100052_bb0235","first-page":"237","article-title":"Prekallikrein Activation in the Adult Respiratory Distress Syndrome","volume":"21","author":"Schapira","year":"1985","journal-title":"Bull Eur Physiopathol Respir"},{"key":"10.1016\/j.medidd.2020.100052_bb0240","doi-asserted-by":"crossref","unstructured":"Farmer SG. The Kallikrein\u2014Kinin System in Asthma and Acute Respiratory Distress Syndrome (Chapter 15), The Kinin System. Handbook of Immunopharmacology,1997, Pages 249\u2013263.","DOI":"10.1016\/B978-012249340-9\/50017-6"},{"key":"10.1016\/j.medidd.2020.100052_bb0245","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.medidd.2020.100052_bb0250","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1389203033487180","article-title":"The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein","volume":"4","author":"Ascenzi","year":"2003","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.medidd.2020.100052_bb0255","doi-asserted-by":"crossref","unstructured":"Engles L. Review and application of serine protease inhibition in coronary artery bypass graft surgery Am J Health Syst Pharm. 2005 Sep 15;62(18 Suppl 4):S9\u201314.","DOI":"10.2146\/ajhp050300"},{"issue":"6 Suppl","key":"10.1016\/j.medidd.2020.100052_bb0260","first-page":"s653","article-title":"Aprotinin: a pharmacologic overview","volume":"27","author":"Levy","year":"2004","journal-title":"Orthopedics."},{"issue":"18 Suppl 4","key":"10.1016\/j.medidd.2020.100052_bb0265","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.2146\/ajhp050302","article-title":"Systemic inflammatory response to coronary artery bypass graft surgery","volume":"62","author":"Hess","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.medidd.2020.100052_bb0270","doi-asserted-by":"crossref","unstructured":"Tain-Yen Hsia 1, Tim C McQuinn, Rupak Mukherjee et al. Effects of Aprotinin or Tranexamic Acid on Proteolytic\/Cytokine Profiles in Infants After Cardiac Surgery. Ann Thorac Surg. 2010 Jun;89(6):1843\u201352.","DOI":"10.1016\/j.athoracsur.2010.02.069"},{"key":"10.1016\/j.medidd.2020.100052_bb0275","unstructured":"\"Bayer Temporarily Suspends Global Trasylol Marketing\" (PDF) (Press release)Trasylol.com. 2007-11-05. Archived from the original (PDF) on 2011-07-17. Retrieved 2007-12-03."},{"key":"10.1016\/j.medidd.2020.100052_bb0280","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa0802395","article-title":"PC. H\u00e9bert PC., Mazer CD. et al. A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery","volume":"358","author":"Fergusson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medidd.2020.100052_bb0285","unstructured":"\"European Medicines Agency recommends lifting suspension of aprotinin\". European Medicines Agency. 2012-02-17."},{"key":"10.1016\/j.medidd.2020.100052_bb0290","unstructured":"The Nordic Group acquires rights to Trasylol\u00ae from Bayer HealthCare\". The Nordic Group B.V. Archived from the original on 1 February 2014. Retrieved 28 January 2014."},{"key":"10.1016\/j.medidd.2020.100052_bb0295","doi-asserted-by":"crossref","unstructured":"Li Zhang,Xiaokai Feng,Danqing Zhang et al.Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome. Circulation, Originally published 18 May 2020. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046702.","DOI":"10.1161\/CIRCULATIONAHA.120.046702"},{"key":"10.1016\/j.medidd.2020.100052_bb0300","unstructured":"Svartholm E., Haglund U., Ljungberg J. et al. Influence of aprotinin, a protease inhibitor, on porcine E. coli shock. Studies on coagulation, fibrinolytic and hemodynamic response. Acta Chirurgica Scandinavica, 01 Jan 1989, 155(1):7\u201313."},{"issue":"1","key":"10.1016\/j.medidd.2020.100052_bb0305","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tox.2008.08.025","article-title":"Evaluation of protease inhibitors and an antioxidant for treatment of sulfur mustard-induced toxic lung injury","volume":"263","author":"Anderson","year":"2009","journal-title":"Toxicology."}],"container-title":["Medicine in Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590098620300397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590098620300397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:40:30Z","timestamp":1762911630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590098620300397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":61,"alternative-id":["S2590098620300397"],"URL":"https:\/\/doi.org\/10.1016\/j.medidd.2020.100052","relation":{},"ISSN":["2590-0986"],"issn-type":[{"value":"2590-0986","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19","name":"articletitle","label":"Article Title"},{"value":"Medicine in Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medidd.2020.100052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100052"}}